Iecure
1 known investors
iECURE develops in vivo genetic therapies using targeted gene insertion and genome editing to treat rare neurometabolic disorders, initially focusing on liver-centered metabolic conditions. The company serves patients with rare genetic diseases through investigational curative therapies.
Investors · 1
Frequently asked questions
- What does Iecure do?
- iECURE develops in vivo genetic therapies using targeted gene insertion and genome editing to treat rare neurometabolic disorders, initially focusing on liver-centered metabolic conditions. The company serves patients with rare genetic diseases through investigational curative therapies.
- Who are Iecure's investors?
- Iecure's investors include OrbiMed.